NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $6.75 -0.30 (-4.26%) Closing price 04:00 PM EasternExtended Trading$6.72 -0.03 (-0.37%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Actuate Therapeutics Stock (NASDAQ:ACTU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Actuate Therapeutics alerts:Sign Up Key Stats Today's Range$6.65▼$7.2950-Day Range$7.05▼$11.3652-Week Range$5.51▼$11.99Volume96,960 shsAverage Volume51,900 shsMarket Capitalization$132.44 millionP/E RatioN/ADividend YieldN/APrice Target$20.50Consensus RatingBuy Company OverviewActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Read More… Actuate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreACTU MarketRank™: Actuate Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 783rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingActuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageActuate Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Actuate Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioActuate Therapeutics has a P/B Ratio of 675.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ACTU. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActuate Therapeutics does not currently pay a dividend.Dividend GrowthActuate Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ACTU. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Actuate Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actuate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Actuate Therapeutics' insider trading history. Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACTU Stock News HeadlinesActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib TrialJune 24 at 9:15 AM | globenewswire.comActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOJune 20, 2025 | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 24, 2025 | Porter & Company (Ad)Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 17, 2025 | tmcnet.comActuate Therapeutics to be included in Russell 3000, Russell 2000 indexesJune 16, 2025 | seekingalpha.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 16, 2025 | globenewswire.comActuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerJune 4, 2025 | seekingalpha.comActuate Therapeutics shares highlights from KOL eventon elraglusib dataJune 3, 2025 | finance.yahoo.comSee More Headlines ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $7.96 at the beginning of 2025. Since then, ACTU stock has decreased by 15.2% and is now trading at $6.75. View the best growth stocks for 2025 here. How were Actuate Therapeutics' earnings last quarter? Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its earnings results on Thursday, May, 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.06. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. Who are Actuate Therapeutics' major shareholders? Top institutional investors of Actuate Therapeutics include Voss Capital LP (0.73%), Sigma Planning Corp (0.12%), Goldman Sachs Group Inc. (0.11%) and Sfmg LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis. View institutional ownership trends. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actuate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings5/15/2025Today6/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CIK1652935 WebN/A Phone(847) 986-4190FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$21.00 Low Stock Price Target$20.00 Potential Upside/Downside+203.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.28 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-339.73% Debt Debt-to-Equity RatioN/A Current Ratio0.46 Quick Ratio0.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book675.00Miscellaneous Outstanding Shares19,620,000Free Float6,015,000Market Cap$132.44 million OptionableN/A BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:ACTU) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.